Gryphon Financial Partners’s iShares Biotechnology ETF IBB Stock Holding History

Gryphon Financial Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-714	Closed	-$84K	–	204
2022 Q2	$84K	Buy	+714	New	+$84.8K	0.02%	194
2021 Q3	–	Sell	-714	Closed	-$117K	–	201
2021 Q2	$117K	Buy	+714	New	+$110K	0.03%	169
2020 Q3	–	Sell	-744	Closed	-$102K	–	152
2020 Q2	$102K	Buy	+744	New	+$94.8K	0.03%	128
2019 Q3	–	Sell	-934	Closed	-$102K	–	166
2019 Q2	$102K	Buy	+934	New	+$99.3K	0.03%	148
2018 Q3	–	Sell	-1,360	Closed	-$149K	–	471
2018 Q2	$149K	Hold	1,360	–	–	0.07%	101
2018 Q1	$145K	Sell	1,360 -110	-7%	-$12.2K	0.07%	105
2017 Q4	$157K	Buy	+1,470	New	+$157K	0.09%	97

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Gryphon Financial Partners's IBB Position: Q3 2022 in Review

Gryphon Financial Partners sold out of iShares Biotechnology ETF (IBB) in Q3 2022, closing a stake of 714 shares — an estimated $84K sold.

Gryphon Financial Partners first reported a position in IBB in Q4 2017 and held it in 7 quarters. The position peaked at $157K in Q4 2017. 829 funds tracked by Wall St. Rank hold IBB as of Q3 2022.

Gryphon Financial Partners reported no remaining iShares Biotechnology ETF position as of Q3 2022 after selling out during the quarter.
Gryphon Financial Partners sold 714 iShares Biotechnology ETF shares in Q3 2022, an estimated $84K.
Gryphon Financial Partners first reported a position in iShares Biotechnology ETF in Q4 2017 and held it in 7 quarters.
Gryphon Financial Partners's iShares Biotechnology ETF position peaked at $157K in Q4 2017.
829 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2022.

Based on Gryphon Financial Partners's 13F filing for Q3 2022, filed 14 Nov 2022.